Kronos Bio Inc (KRON) Stock Price, Quote & News

Latest News on KRON

Mar 18, 2025, 4:01 PM EDT - 5 weeks ago

Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results

Nov 27, 2024, 7:30 AM EST - 5 months ago

Kronos Bio Announces CEO Transition and Reduction in Force

Nov 14, 2024, 4:02 PM EST - 5 months ago

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024

Oct 23, 2024, 8:55 AM EDT - 6 months ago

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors

Oct 9, 2024, 8:55 AM EDT - 7 months ago

Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors

Oct 7, 2024, 8:55 AM EDT - 7 months ago

Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren's Disease

Sep 25, 2024, 8:55 AM EDT - 7 months ago

Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy

Sep 23, 2024, 8:55 AM EDT - 7 months ago

Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer

Sep 3, 2024, 8:55 AM EDT - 8 months ago

Kronos Bio Announces Participation in Medical and Investor Conferences in September

Jul 23, 2024, 4:15 PM EDT - 9 months ago

Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer

May 23, 2024, 5:15 PM EDT - 1 year ago

Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2024, 4:30 PM EDT - 1 year ago

Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events

May 21, 2024, 8:15 AM EDT - 1 year ago

Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer

May 9, 2024, 4:05 PM EDT - 1 year ago

Kronos Bio Reports First-Quarter 2024 Financial Results

May 6, 2024, 6:40 PM EDT - 1 year ago

Kronos Bio: Underestimated Drug Discovery Platform

Mar 21, 2024, 7:05 AM EDT - 1 year ago

Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results

Mar 12, 2024, 8:00 AM EDT - 1 year ago

How Does Kronos Stock Look After Its 15% Rise Last Week?

Mar 7, 2024, 4:05 PM EST - 1 year ago

Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway

Mar 5, 2024, 4:44 PM EST - 1 year ago

Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting

Feb 27, 2024, 4:05 PM EST - 1 year ago

Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference

Jan 25, 2024, 8:00 AM EST - 1 year ago

Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement

Dec 18, 2023, 4:06 PM EST - 1 year ago

Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate

Dec 4, 2023, 8:00 AM EST - 1 year ago

Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Nov 27, 2023, 4:05 PM EST - 1 year ago

Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference

Nov 13, 2023, 4:05 PM EST - 1 year ago

Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results

Nov 2, 2023, 4:05 PM EDT - 1 year ago

Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 Study

Nov 2, 2023, 12:00 PM EDT - 1 year ago

Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting

Oct 27, 2023, 8:00 AM EDT - 1 year ago

Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting

Oct 13, 2023, 12:30 PM EDT - 1 year ago

Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC

Oct 4, 2023, 4:05 PM EDT - 1 year ago

Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13

Aug 17, 2023, 8:00 AM EDT - 1 year ago

Kronos Bio Announces Departure of Chief Financial Officer and Head of Corporate Development

Aug 8, 2023, 4:05 PM EDT - 1 year ago

Kronos Bio Reports Recent Business Progress and Second-Quarter 2023 Financial Results

Jun 6, 2023, 8:00 AM EDT - 2 years ago

Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance

Jun 1, 2023, 4:05 PM EDT - 2 years ago

Kronos Bio Announces Participation in Upcoming Investor Conferences

May 10, 2023, 4:05 PM EDT - 2 years ago

Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial Results

Apr 24, 2023, 4:05 PM EDT - 2 years ago

Kronos Bio Appoints Roger Dansey, M.D., to Board of Directors

Apr 11, 2023, 4:05 PM EDT - 2 years ago

Kronos Bio Announces Changes to Board of Directors

Mar 15, 2023, 4:05 PM EDT - 2 years ago

Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2022 Financial Results

Feb 28, 2023, 4:05 PM EST - 2 years ago

Kronos Bio Announces Participation in 43rd Annual Cowen Health Care Conference

Jan 9, 2023, 8:23 AM EST - 2 years ago

Kronos Bio's stock rallies after announcing drug-discovery deal with Roche

Jan 9, 2023, 7:00 AM EST - 2 years ago

Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology

Dec 11, 2022, 10:00 AM EST - 2 years ago

Kronos Bio Presents Preclinical Data Supporting Anti-Leukemic Activity of Lanraplenib in Combination with Multiple Targeted Agents in Acute Myeloid Leukemia (AML) Preclinical Models at American Society of Hematology Meeting

Dec 7, 2022, 4:05 PM EST - 2 years ago

Kronos Bio Announces Selection of Recommended Phase 2 Dose for its Oral CDK9 Inhibitor, KB-0742, After Reaching Target Engagement Goal with Acceptable Safety Profile in Ongoing Phase 1/2 Clinical Trial

Nov 8, 2022, 4:10 PM EST - 2 years ago

Kronos Bio Reports Recent Business Progress and Third-Quarter 2022 Financial Results

Nov 8, 2022, 4:05 PM EST - 2 years ago

Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742

Oct 12, 2022, 4:04 AM EDT - 2 years ago

Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Pediatric Cancer Models in Poster Presentation at EORTC-NCI-AACR 2022

Sep 6, 2022, 4:05 PM EDT - 2 years ago

Kronos Bio Announces Participation in H.C. Wainwright 24th Annual Global Investment Conference

Aug 22, 2022, 8:00 AM EDT - 2 years ago

Kronos Bio Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Lanraplenib in Combination with Gilteritinib in Acute Myeloid Leukemia

Aug 16, 2022, 4:05 PM EDT - 2 years ago

Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML

Aug 4, 2022, 4:05 PM EDT - 2 years ago

Market Cap	47.50M
Revenue (ttm)	9.85M
Net Income (ttm)	-86.08M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-873.91%
Debt to Equity Ratio	0.00

Volume	101,900
Avg Vol	142,806
Day's Range	N/A - N/A
Shares Out	60.97M
Stochastic %K	27%
Beta	1.78
Analysts	Strong Sell
Price Target	$2.25